FeesSafety
Pluang+

ARS Pharmaceuticals sees 42% demand rise but modest revenue growth; targets cash flow breakeven by 2027

Company Fundamentals
18 Nov 2026, 14:30 WIB
Seeking Alpha
View Source
Neutral
ARS Pharmaceuticals sees 42% demand rise but modest revenue growth; targets cash flow breakeven by 2027

ARS Pharmaceuticals reported a 42% increase in end-user demand but only a 7% growth in U.S. net product revenue. The company holds a 9% market share in targeted accounts and maintains a gross-to-net ratio around 50%. SPRY reduced quarterly SG&A expenses to $43.5 million and aims for cash flow breakeven by the end of 2027, though liquidity dropped to $138.4 million. The ARS-2 interim study results are expected in the first quarter of 2027, with the stock trading near sector averages at 3.48x forward EV/sales.

ARS Pharmaceuticals shows a 42% increase in end-user demand while revenue growth remains modest. For readers following the health sector, here is Pluang's market snapshot as of Nov 18, 2026 19:21 WIB: out of 150 priced health-sector US stocks, 55 rose and 86 fell today. Notable movers include BKD at USD 8.60 with a 1-day change of -2.27%, FLNA at USD 0.47 with 97% sell order activity, and TNGX at USD 22.60 with a 1-day change of +2.22%. Typical hold times on Pluang range from 5 to 39 days among these stocks.

More News

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
24 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgrades Charles Schwab to Strong Buy as client assets hit $13.27T in Oct 2026

Raymond James upgraded Charles Schwab to Strong Buy following strong growth in October 2026. Client assets rose 12% year over year to $13.27 trillion, with core net new assets surging 50% to $66.5 billion, a record for the month. Schwab also opened 4...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App